SYT17抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse kidney tissue, Primary antibody: P00718(SYT17 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00718(SYT17 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P00718(SYT17 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Synaptotagmin 17 (SYT17) is a member of the synaptotagmin family, a group of membrane-trafficking proteins characterized by calcium-binding C2 domains. While many synaptotagmins regulate synaptic vesicle exocytosis in neuronal signaling, SYT17 is distinct in both structure and function. Unlike its calcium-sensitive counterparts, SYT17 lacks critical residues for calcium coordination in its C2 domains, suggesting alternative regulatory mechanisms. It is broadly expressed in the central nervous system (e.g., hippocampus, cortex) and peripheral tissues (e.g., pancreas, kidney), where it localizes to the Golgi apparatus, vesicles, and autophagosomal membranes.

SYT17 antibodies are essential tools for studying its roles in intracellular trafficking, autophagy, and organelle dynamics. Research links SYT17 to secretory pathways in endocrine cells, lysosomal repair, and neural development. Its dysfunction has been implicated in neurodegenerative diseases and cancer progression, though mechanistic insights remain limited. For example, SYT17 depletion disrupts Golgi structure and protein secretion, while its overexpression correlates with poor prognosis in gliomas.

Commercial SYT17 antibodies are typically validated for applications like Western blotting, immunofluorescence, and immunohistochemistry. However, specificity challenges arise due to sequence homology with other synaptotagmins, necessitating careful validation via knockout controls. Ongoing studies aim to clarify SYT17's interplay with other trafficking proteins and its potential as a therapeutic target.